Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers

医学 正电子发射断层摄影术 免疫疗法 核医学 计算机断层摄影术 正电子发射断层摄影术 正电子发射 放射科 正电子 断层摄影术 癌症 癌症研究 内科学 物理 核物理学 电子
作者
Hina Shah,Yating Wang,Su–Chun Cheng,Lauren Gunasti,Yu‐Hui Chen,Ana Lako,Jeffrey P. Guenette,Scott J. Rodig,Vickie Y. Jo,Ravindra Uppaluri,Robert I. Haddad,Jonathan Daniel Schoenfeld,Heather A. Jacene
出处
期刊:JAMA otolaryngology-- head & neck surgery [American Medical Association]
卷期号:148 (3): 268-268 被引量:19
标识
DOI:10.1001/jamaoto.2021.4052
摘要

IMPORTANCE: Neoadjuvant immunotherapy is a novel approach with the potential to improve outcomes for patients with oral cavity squamous cell cancer (OCSCC). Adverse events of varying severity are reported with immunotherapy, and a biomarker to predict response would be clinically useful to avoid toxic effects in those unlikely to benefit. OBJECTIVE: To correlate changes on fluoro-[18F]-deoxy-2-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) scans with primary tumor pathologic response and immunologic biomarkers in patients with OCSCC receiving neoadjuvant immunotherapy. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective analysis of serial FDG-PET/CT scans obtained prospectively as part of a phase 2 open-label randomized clinical trial investigating neoadjuvant immunotherapy in patients with untreated OCSCC between 2016 and 2019. Included were a total of 29 patients from a single academic medical center with untreated OCSCC (≥T2, or clinically node positive) randomized 1:1 to receive neoadjuvant therapy with single agent nivolumab or combination nivolumab and ipilimumab followed by surgery and standard of care adjuvant therapy. INTERVENTIONS: The interventions in this study were FDG-PET/CT scans before (T0) and after (T1) preoperative immunotherapy. MAIN OUTCOMES AND MEASURES: Data collected from FDG-PET/CT scans included maximum standardized uptake value (SUVmax) of primary OCSCC and cervical lymph nodes (LNs) at T0 and T1 and new LN uptake and uptake consistent with radiologic immune-related adverse events (irAEs) at T1. Primary OCSCC pathologic response reported as percentages of viable vs nonviable tumor. The number of CD8+ cells/mm2 was determined in the primary tumor biopsy specimen and at surgery. RESULTS: There was no correlation between pathologic response and change in SUVmax in the primary OCSCC between T0 and T1. Out of 27 total participants, 13 had newly FDG-avid ipsilateral LNs at T1, most negative on pathology. A total of 9 had radiologic irAEs, most commonly sarcoid-like LN (7 of 27). No correlations were found between primary OCSCC SUVmax at T0 and CD8+ T-cell number in the primary tumor biopsy, and no correlations were found between primary OCSCC SUVmax at T1 and CD8+ T-cell number in the primary tumor at surgery. CONCLUSIONS AND RELEVANCE: There were no correlations between changes in FDG uptake after neoadjuvant immunotherapy and pathologic primary tumor response. Importantly, newly FDG-avid ipsilateral LNs following neoadjuvant immunotherapy were commonly observed but did not represent progressive disease or indicate pathologically disease positive nodes in most cases. These findings argue against altering surgical plans in this setting and suggest that the role of FDG-PET/CT may be limited as an early imaging biomarker for predicting pathologic response to preoperative immunotherapy for OCSCC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02919683.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
GXY发布了新的文献求助10
刚刚
1秒前
1秒前
爆米花的应助被聪明皮卡丘采纳,获得10
1秒前
cyf完成签到,获得积分20
1秒前
1秒前
泽_泽发布了新的文献求助10
2秒前
Liyingm完成签到,获得积分10
2秒前
铃木卿发布了新的文献求助10
4秒前
向天一发布了新的文献求助10
4秒前
5秒前
宝儿姐完成签到,获得积分10
5秒前
jiecom完成签到 ,获得积分10
5秒前
同心源发布了新的文献求助20
5秒前
6秒前
7秒前
8秒前
8秒前
8秒前
8秒前
俏皮的灵阳完成签到,获得积分10
9秒前
李渠发布了新的文献求助10
10秒前
10秒前
syvshc的应助被香香香采纳,获得10
10秒前
11秒前
11秒前
君无邪完成签到,获得积分10
11秒前
11秒前
飞远完成签到,获得积分10
11秒前
顾矜的应助被donkey采纳,获得10
11秒前
12秒前
12秒前
李爱国的应助被mmmm采纳,获得10
12秒前
12秒前
小宋发布了新的文献求助10
12秒前
pure发布了新的文献求助10
12秒前
13秒前
君无邪发布了新的文献求助10
13秒前
肆先森完成签到,获得积分10
14秒前
tsl发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187707
求助须知:如何正确求助?哪些是违规求助? 9575782
关于积分的说明 21843037
捐赠科研通 7785576
什么是DOI,文献DOI怎么找? 3435097
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2481986